AstraZeneca社、Genedata Screenerの利用拡大：
グローバル全拠点でスクリーニング業務をデジタル化

Genedata Screener to be adopted worldwide at AstraZeneca for all in-vitro testing, focusing on biotherapeutics discovery as well as specialized modalities of PROTACs and CRISPR.

December 7, 2021
Basel, Switzerland

Genedata, a leading provider of enterprise software solutions for biopharma R&D, today announced an expanded licensing agreement with AstraZeneca for Genedata Screener^® which will support the company’s aim to digitalize and automate its screening processes. The broad adoption of the platform will enable AstraZeneca’s research labs in Europe and North America to further automate routine in-vitro testing, with an increasing focus on biotherapeutics and specialized modalities such as PROTACs and CRISPR.
  
Genedata Screener consolidates data management and analysis for all screening and assay development operations. It minimizes maintenance costs while continually evolving to support customers’ most recent screening technologies and assay designs. 

“The Genedata Screener platform enables us to digitalize and harmonize assay data management, analysis, and reporting across a range of therapeutic modalities,” said Jon Wingfield, Ph.D., Principal Scientist, Discovery Sciences, R&D, AstraZeneca. “It captures and secures raw experimental data in a central repository, analyses them using standardized workflows, automatically annotates them, and provides access to those results to AstraZeneca researchers.” 

The expanded licensing of Genedata Screener by AstraZeneca continues a successful collaboration between the two companies spanning ten years, driving innovation and increasing the efficiency of drug discovery processes. Automating complex assay data analysis workflows to deliver high-quality results in real-time, Genedata Screener was initially used by AstraZeneca during early-stage lead discovery only. Today, the platform is used further downstream in R&D and is widely used in specialized screening workflows in therapeutic areas such as oncology, cardiovascular, respiratory and immunology diseases. 

With drug discovery trending towards more biologically relevant and complex assays, Screener has expanded towards supporting innovative assay technologies, such as:

• Mass Spectrometry-based assays that are extremely information-rich and increasingly used in early discovery and mode-of-action analysis.
• High Content Screening for applications such as target identification, stem cell differentiation, multiplexed cell painting assays and in-vitro toxicity screening and antibody internalization studies optimized via Artificial Intelligence.

“We are proud to continue our successful collaboration with AstraZeneca,” noted Othmar Pfannes, Ph.D., CEO of Genedata, “But more importantly, we’re excited by the scientific innovations that this collaboration brings. With unparalleled support for automation initiatives that shorten project timelines, Genedata Screener enables AstraZeneca to focus its resources on innovative biological approaches and cutting-edge screening technologies.”